久久av无码精品人妻糸列,粉嫩国产白浆在线观看

JNJ-7706621

NMR下載 COA and HPLC MSDS下載
names：
JNJ-7706621
CAS號：
443797-96-4
MDL Number： MFCD11100270
MF(分子式)： C15H12F2N6O3S MW(分子量)： 394.36
EINECS: Reaxys Number:
Pubchem ID:5330790 Brand:BIOFOUNT

JNJ-7706621(cas:443797-96-4) 是一種有效的 aurora kinase 抑制劑，同時能有效抑制 CDK1 和 CDK2，對 CDK1，CDK2，aurora-A 和 aurora-B 的 IC₅₀ 值分別為 9 nM，3 nM，11 nM 和 15 nM。

貨品編碼	規(guī)格	純度	價格 (￥)	現(xiàn)價(￥)	特價(￥)	庫存描述	數(shù)量	總計 (￥)
YZM001241-5mg	5mg	99.9%	￥ 1417.00	￥ 1417.00		2-3天	- +	￥ 0.00
YZM001241-2mg	2mg	99.9%	￥ 780.00	￥ 780.00		2-3天	- +	￥ 0.00

大包裝詢價提供各種包裝，敬請垂詢
收藏商品商品點評加入購物車立即購買

快速詢價

收起

你想詢價的產(chǎn)品

*產(chǎn)品名稱：

CAS號：

產(chǎn)品編號：

需求描述：

請準確填寫您的聯(lián)系方式，以便為您提供最好的服務(wù)。

*公司名稱：

*電子郵箱：

聯(lián)系人：

*電話：

*驗證碼：

詢價

中文別名	JNJ-7706621(443797-96-4);JNJ 7706621
英文別名	JNJ-7706621(443797-96-4)
CAS號	443797-96-4
Inchi	InChI=1S/C15H12F2N6O3S/c16-10-2-1-3-11(17)12(10)13(24)23-14(18)21-15(22-23)20-8-4-6-9(7-5-8)27(19,25)26/h1-7H,(H2,19,25,26)(H3,18,20,21,22)
InchiKey	KDKUVYLMPJIGKA-UHFFFAOYSA-N
分子式 Formula	C15H12F2N6O3S
分子量 Molecular Weight	394.36
溶解度Solubility	生物體外In Vitro:DMSO溶解度≥ 125 mg/mL(316.97 mM)*"≥" means soluble可溶, but saturation unknown溶解度未知.
性狀	白色至灰白色固體粉末
儲藏條件 Storage conditions	短期1-2周儲存在-4℃條件下就行，長期儲存（1-2年）需在-20℃條件下存儲

JNJ-7706621(443797-96-4)實驗注意事項：
1.實驗前需戴好防護眼鏡，穿戴防護服和口罩，佩戴手套，避免與皮膚接觸。
2.實驗過程中如遇到有毒或者刺激性物質(zhì)及有害物質(zhì)產(chǎn)生，必要時實驗操作需要手套箱內(nèi)完成以免對實驗人員造成傷害
3.實驗后產(chǎn)生的廢棄物需分類存儲，并交于專業(yè)生物廢氣物處理公司處理，以免造成環(huán)境污染

JNJ-7706621(443797-96-4) Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tag:JNJ-7706621(443797-96-4),JNJ-7706621試劑,JNJ-7706621的外觀,JNJ-7706621的作用,JNJ-7706621的溶解度,JNJ-7706621的生產(chǎn),JNJ-7706621的合成路線,JNJ-7706621的廠家,JNJ-7706621的價格,JNJ-7706621的MSDS,JNJ-7706621的注意事項

產(chǎn)品說明	JNJ-7706621(443797-96-4)是一種新型的細胞周期抑制劑，它對幾種細胞周期蛋白依賴性激酶（CDK）和Aurora激酶具有有效的抑制作用
Introduction	JNJ-7706621 (443797-96-4) is a new type of cell cycle inhibitor, which has an effective inhibitory effect on several cyclin-dependent kinases (CDK) and Aurora kinase
Application1	In human cancer cells, treatment with JNJ-7706621 inhibited cell growth independent of p53, retinoblastoma, or P-glycoprotein status; activated apoptosis; and reduced colony formation.
Application2	At low concentrations, JNJ-7706621 slowed the growth of cells and at higher concentrations induced cytotoxicity.
Application3	JNJ-7706621(443797-96-4)選擇性地阻斷了各種來源的腫瘤細胞的增殖，但在抑制正常人細胞生長方面的作用卻降低了約10倍。

警示圖
危險性	warning
危險性警示	Not available
安全聲明	H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對身體有害
安全防護	P264處理后徹底清洗+P280戴防護手套/穿防護服/戴防護眼罩/戴防護面具+P305如果進入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡（如果有）并且易于操作,繼續(xù)沖洗+P337如果眼睛刺激持續(xù)+P2393獲得醫(yī)療建議/護理
備注	實驗過程中防止吸入、食入，做好安全防護

Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells(Breast Cancer Research and Treatment,2015)

Allosteric modulation of AURKA kinase activity by a small-molecule inhibitor of its protein-protein interaction with TPX2(Scientific Reports,2016)

Multi-kinase inhibitors, AURKs and cancer(Medical Oncology,2016)

Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer(BMC Cancer,2015)

Antiproliferation Inhibitors Targeting Aurora Kinases(Checkpoint Responses in Cancer Therapy,2008)

1.Synthesis and evaluation of N-acyl sulfonamides as potential prodrugs of cyclin-dependent kinase inhibitor JNJ-7706621.
Huang S1, Connolly PJ, Lin R, Emanuel S, Middleton SA. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3639-41. Epub 2006 May 6.
A novel prodrug strategy for cyclin-dependent kinase inhibitor JNJ-7706621 has been explored. Through N-acylation of a sulfonamide substituent, tails containing different solubilizing groups (amino, carboxyl, alkoxyl, and hydroxyl) were attached to JNJ-7706621. Most of the prodrugs exhibited good aqueous solubility and the N-acyl groups on the sulfonamide were metabolically cleaved to generate active drug in rat PK study.

2.Active and passive tumor targeting of a novel poorly soluble cyclin dependent kinase inhibitor, JNJ-7706621.
Danhier F1, Ucakar B, Magotteaux N, Brewster ME, Préat V. Int J Pharm. 2010 Jun 15;392(1-2):20-8. doi: 10.1016/j.ijpharm.2010.03.018. Epub 2010 Mar 11.
The anti-cancer cyclin dependent kinase (CDK) inhibitors are poorly soluble drugs. The aims of this work were (i) to formulate a novel CDK inhibitor, JNJ-7706621, in polymeric micelles and nanoparticles, (ii) to compare passive and active targeting on tumor growth and (iii) to evaluate the potential synergy of JNJ-7706621 with Paclitaxel. Therefore, JNJ-7706621 was encapsulated in self-assembling diblock copolymers made up of epsilon-caprolactone (CL) and trimethylene carbonate (TMC) (PEG-p-(CL-co-TMC)) polymeric micelles and in (poly(lactide-co-glycolide)) (PLGA)-based PEGylated nanoparticles (passive targeting) as well as in RGD-grafted nanoparticles (active targeting). In vivo, the transplantable liver tumor growth was more decreased by active targeting with RGD-grafted nanoparticles than by passive targeting with micelles or ungrafted nanoparticles. Moreover, a synergy between JNJ-7706621 and Paclitaxel was demonstrated. Therefore, active targeting of JNJ-7706621-loaded nanocarriers may be considered as an effective anti-cancer drug delivery system for cancer chemotherapy, particularly in combination with Paclitaxel.

3.Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases.
Matsuhashi A1, Ohno T, Kimura M, Hara A, Saio M, Nagano A, Kawai G, Saitou M, Takigami I, Yamada K, Okano Y, Shimizu K. Curr Cancer Drug Targets. 2012 Jul;12(6):625-39.
Aurora kinases and cyclin-dependent kinases, which play critical roles in the cell cycle and are frequently overexpressed in a variety of tumors, have been suggested as attractive targets for cancer therapy. JNJ-7706621, a recently identified dual inhibitor of these kinases, is reported to induce cell cycle arrest, endoreduplication, and apoptosis. In the present study, we further investigated the molecular mechanisms underlying these effects. The inhibitor arrested various cells at G2 phase at low concentration, and at both G1 and G2 phases at high concentration. JNJ-7706621 did not prevent localization of Aurora A to the spindle poles, but did inhibit other centrosomal proteins such as TOG, Nek2, and TACC3 in early mitotic phase. Similarly, the drug did not prevent localization of Aurora B to the kinetochore, but did inhibit other chromosomal passenger proteins such as Survivin and INCENP. In the cells exposed to JNJ-7706621 after nocodazole release, Aurora B, INCENP, and Survivin became relocated to the peripheral region of chromosomes, but Plk1 and Prc1 were localized on microtubules in later mitotic phase.

對不起，暫無產(chǎn)品評價！

MSDS

SDS 1.0 中文

展開

SDS 1.0 英文

展開